Drug intelligence / Profile preview

Gluscan

Development stage: Unknown
Lead developer: Advanced Accelerator Applications
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

**Gluscan** is a branded radiopharmaceutical containing fludeoxyglucose (18F), a fluorine-18-labeled glucose analog used as a positron emission tomography (PET) imaging agent. It assesses glucose metabolism, which is elevated in cancer cells, aiding in tumor detection, staging, and monitoring, as well as diagnosing heart disease and epilepsy. Developed by Advanced Accelerator Applications (AAA), now part of Novartis, it is administered intravenously under medical supervision for diagnostic purposes only, with a short shelf life due to the radioactive isotope.[1][2][3][5][9]

Brand names: Gluscan
Other names: Gluscan 500Gluscan500Gluscan-500Gluscan 600 MBq/mLGluscan FDG

Targets

GLUT9 (Glucose transporter type 9)

Beyond the preview

Go deeper on Gluscan.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Gluscan.

Explore the full profile